GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » PB Ratio

Aceragen (Aceragen) PB Ratio : 0.14 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Aceragen's share price is $0.38. Aceragen's Book Value per Share for the quarter that ended in Mar. 2023 was $2.70. Hence, Aceragen's PB Ratio of today is 0.14.

Good Sign:

Aceragen Inc stock PB Ratio (=0.14) is close to 10-year low of 0.14

The historical rank and industry rank for Aceragen's PB Ratio or its related term are showing as below:

ACGN' s PB Ratio Range Over the Past 10 Years
Min: 0.14   Med: 3.12   Max: 25.96
Current: 0.14

During the past 13 years, Aceragen's highest PB Ratio was 25.96. The lowest was 0.14. And the median was 3.12.

ACGN's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.385 vs ACGN: 0.14

During the past 12 months, Aceragen's average Book Value Per Share Growth Rate was -66.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Aceragen was 211.00% per year. The lowest was -38.00% per year. And the median was 40.85% per year.

Back to Basics: PB Ratio


Aceragen PB Ratio Historical Data

The historical data trend for Aceragen's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen PB Ratio Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 - - 1.02 1.84

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 1.15 1.06 1.84 0.85

Competitive Comparison of Aceragen's PB Ratio

For the Biotechnology subindustry, Aceragen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aceragen's PB Ratio falls into.



Aceragen PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aceragen's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2023)
=0.38/2.701
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aceragen  (NAS:ACGN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aceragen PB Ratio Related Terms

Thank you for viewing the detailed overview of Aceragen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341

Aceragen (Aceragen) Headlines

From GuruFocus

Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study

By Stock market mentor Stock market mentor 02-06-2023

Idera Pharmaceuticals Announces Tilsotolimod Updates

By GuruFocusNews GuruFocusNews 12-14-2021